Regnum Corp

PINK:RGMP USA Entertainment
Market Cap
$2.29K
Market Cap Rank
#50580 Global
#15459 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$1.20
About

Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.

Regnum Corp (RGMP) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of March 2023: 0.237x

Based on the latest financial reports, Regnum Corp (RGMP) has a cash flow conversion efficiency ratio of 0.237x as of March 2023.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-320.50K) by net assets ($-1.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Regnum Corp - Cash Flow Conversion Efficiency Trend (2017–2022)

This chart illustrates how Regnum Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Regnum Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Regnum Corp ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Regnum Corp (2017–2022)

The table below shows the annual cash flow conversion efficiency of Regnum Corp from 2017 to 2022.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2022-12-31 $-1.16 Million $-705.55K 0.608x +1893.60%
2021-12-31 $-379.82K $-11.58K 0.030x -58.16%
2020-12-31 $-50.39K $-3.67K 0.073x +101.44%
2019-12-31 $7.68K $-38.85K -5.059x -5610.19%
2018-12-31 $44.06K $4.04K 0.092x -62.19%
2017-12-31 $12.56K $3.05K 0.243x --